ビタミンD3は,TRPV1-MAPKシグナル伝達経路を通じて,潰瘍性大腸炎の改善を媒介する
Keke Zhao1, Jian Li1, Yersen Asai1
1The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Frontiers in immunology
|February 16, 2026
まとめ
ビタミンD3 (VD3) は,TRPV1-MAPK経路をダウンレギュレーションし,炎症を軽減し,腸の障壁機能を回復することによって,潰瘍性大腸炎 (UC) に対して保護します. これはUC患者のための新しい治療の機会を提供します.
科学分野:
- 胃腸内科 胃腸内科
- 免疫学 免疫学とは
- 分子生物学は分子生物学である.
背景:
- 潰瘍性大腸炎 (UC) は,不明確な病原性を持つ複雑な炎症性腸疾患です.
- トランジエント受容体潜在バニロイド1 (TRPV1) とミトゲン活性化タンパク質キナーゼ (MAPK) 経路は炎症に関与しています.
- これらの経路経由によるUCにおけるビタミンD3 (VD3) の潜在的な保護的役割は不明である.
研究 の 目的:
- UCにおけるTRPV1-MAPK経路の役割を調査する.
- この経路を調節することによって,UCに対するVD3の治療効果を評価する.
- VD3のカルシウムホメオスタシスとUCにおける腸のバリア機能への影響を調査する.
主な方法:
- UC患者の結腸組織とデクストラン硫酸ナトリウム (DSS) 誘発の歯類を検査した.
- 疾患活動,結腸組織学,細胞アポトーシスに対するVD3介入効果を評価した.
- TRPV1とMAPK経路のコンポーネントの遺伝子/タンパク質発現を分析した.
- マクロファージのTRPV1局所化のために免疫光を用いて,血清カルシウム濃度を測定した.
主要な成果:
- TRPV1-MAPK経路はUCモデルで上位調節された.
- VD3治療はUCのフェノタイプを改善し,体重減少を減らし,結腸組織学を改善しました.
- VD3はTRPV1発現を低下させ,特にマクロファージに作用し,カルシウムホメオスタシスを調節した.
- VD3は炎症誘発性サイトカインを抑制し,オークルジンとムシン2を上調することで腸のバリア機能を回復させた.
結論:
- VD3は,TRPV1-MAPK経路を調節することにより,UCにおける保護効果を発揮する.
- VD3は免疫反応と腸のバリア機能を調節し,UCに対する新しい治療戦略を提供します.
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
544
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
544
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
915
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
915
Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management
795
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
795
Peptic Ulcer Disease II: Pathophysiology
2.3K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K


